RU2010129685A - Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом - Google Patents
Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом Download PDFInfo
- Publication number
- RU2010129685A RU2010129685A RU2010129685/15A RU2010129685A RU2010129685A RU 2010129685 A RU2010129685 A RU 2010129685A RU 2010129685/15 A RU2010129685/15 A RU 2010129685/15A RU 2010129685 A RU2010129685 A RU 2010129685A RU 2010129685 A RU2010129685 A RU 2010129685A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- probiotic
- composition
- bifidobacterium
- opportunistic infections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
1. Композиция, подходящая для применения в предупреждении оппортунистических инфекций у индивидуумов с нарушенным иммунитетом, содержащая пробиотик Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve или Bifidobacterium longum и фукозилированный олигосахарид, выбираемый из группы, состоящей из 2'-фукозиллактозы, 3'-фукозиллактозы, дифукозиллактозы, лакто-N-фукопентаозы, лакто-N-фукогексаозы, фукозиллакто-N-гексаозы и фукозиллакто-N-неогексаозы. ! 2. Композиция по п.1, в которой фукозилированным олигосахаридом является 2'-фукозиллактоза. ! 3. Композиция по п.1 или 2, в которой пробиотиком является Bifidobacterium lactis CNCM 1-3446 или Bifidobacterium longum АТСС BAA-999. ! 4. Композиция по п.1, которая является детской смесью. ! 5. Композиция по п.4, которая содержит от 0,1 до 3 г фукозилированного олигосахарида на 100 г композиции. ! 6. Композиция по п.4 или 5, которая содержит от 103 до 1012 КОЕ пробиотика на 1 г детской смеси. ! 7. Композиция по п.5, которая содержит от 106 до 109 КОЕ пробиотика на 1 г детской смеси. ! 8. Композиция по п.5, которая дополнительно содержит по меньшей мере один пребиотик в количестве от 0,3 до 19 мас.% от композиции. ! 9. Композиция по п.1, которая является биологически активной добавкой и которая содержит в разовой дозе от 0,1 до 3 г фукозилированного олигосахарида и от 105 до 1012 КОЕ пробиотика. ! 10. Применение композиции по любому из пп.1-9 в производстве лекарственных средств или терапевтической питательной композиции для предупреждения оппортунистических инфекций у индивидуумов с нарушенным иммунитетом. ! 11. Применение по п.10, в котором возбудителем оппортунистической инфекции является Pseudomonas aeroginosa. ! 12. Применение по п.10, в котором инфекция, возбуждаемая Pseudomonas aeroginosa, явл�
Claims (12)
1. Композиция, подходящая для применения в предупреждении оппортунистических инфекций у индивидуумов с нарушенным иммунитетом, содержащая пробиотик Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve или Bifidobacterium longum и фукозилированный олигосахарид, выбираемый из группы, состоящей из 2'-фукозиллактозы, 3'-фукозиллактозы, дифукозиллактозы, лакто-N-фукопентаозы, лакто-N-фукогексаозы, фукозиллакто-N-гексаозы и фукозиллакто-N-неогексаозы.
2. Композиция по п.1, в которой фукозилированным олигосахаридом является 2'-фукозиллактоза.
3. Композиция по п.1 или 2, в которой пробиотиком является Bifidobacterium lactis CNCM 1-3446 или Bifidobacterium longum АТСС BAA-999.
4. Композиция по п.1, которая является детской смесью.
5. Композиция по п.4, которая содержит от 0,1 до 3 г фукозилированного олигосахарида на 100 г композиции.
6. Композиция по п.4 или 5, которая содержит от 103 до 1012 КОЕ пробиотика на 1 г детской смеси.
7. Композиция по п.5, которая содержит от 106 до 109 КОЕ пробиотика на 1 г детской смеси.
8. Композиция по п.5, которая дополнительно содержит по меньшей мере один пребиотик в количестве от 0,3 до 19 мас.% от композиции.
9. Композиция по п.1, которая является биологически активной добавкой и которая содержит в разовой дозе от 0,1 до 3 г фукозилированного олигосахарида и от 105 до 1012 КОЕ пробиотика.
10. Применение композиции по любому из пп.1-9 в производстве лекарственных средств или терапевтической питательной композиции для предупреждения оппортунистических инфекций у индивидуумов с нарушенным иммунитетом.
11. Применение по п.10, в котором возбудителем оппортунистической инфекции является Pseudomonas aeroginosa.
12. Применение по п.10, в котором инфекция, возбуждаемая Pseudomonas aeroginosa, является инфекцией дыхательных, мочевых или желудочно-кишечного путей.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07123390.2 | 2007-12-17 | ||
| EP07123390A EP2072052A1 (en) | 2007-12-17 | 2007-12-17 | Prevention of opportunistic infections in immune-compromised subjects |
| PCT/EP2008/066850 WO2009077352A1 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010129685A true RU2010129685A (ru) | 2012-01-27 |
| RU2486910C2 RU2486910C2 (ru) | 2013-07-10 |
Family
ID=39111664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010129685/15A RU2486910C2 (ru) | 2007-12-17 | 2008-12-05 | Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9217133B2 (ru) |
| EP (2) | EP2072052A1 (ru) |
| CN (1) | CN101909644A (ru) |
| AU (1) | AU2008337646B2 (ru) |
| BR (1) | BRPI0820837A2 (ru) |
| CA (1) | CA2709396A1 (ru) |
| ES (1) | ES2576642T3 (ru) |
| IN (1) | IN2010DE04311A (ru) |
| MX (1) | MX2010006690A (ru) |
| MY (1) | MY185938A (ru) |
| PH (1) | PH12010501367B1 (ru) |
| PL (1) | PL2234627T3 (ru) |
| PT (1) | PT2234627T (ru) |
| RU (1) | RU2486910C2 (ru) |
| SG (1) | SG186657A1 (ru) |
| UA (1) | UA102830C2 (ru) |
| WO (1) | WO2009077352A1 (ru) |
| ZA (1) | ZA201005088B (ru) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7871785B2 (en) | 2007-09-07 | 2011-01-18 | Children's Hospital Medical Center | Use of secretor, Lewis and sialyl antigen levels in clinical samples as predictors of risk for disease |
| EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
| EP2451462B1 (en) | 2009-07-06 | 2017-09-06 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
| ES2989649T3 (es) * | 2009-07-15 | 2024-11-27 | Nutricia Nv | Mezcla de oligosacáridos no digeribles para estimular el sistema inmunitario |
| EP2813230A1 (en) | 2009-07-15 | 2014-12-17 | N.V. Nutricia | Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing infections |
| US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
| US9408880B2 (en) | 2013-12-20 | 2016-08-09 | Katherine Rose Kovarik | Method and system for prevention and treatment of allergic and inflammatory diseases |
| US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| CN102946742A (zh) * | 2010-04-27 | 2013-02-27 | N·V·努特里奇亚 | 人乳寡糖在婴儿营养物中的用途 |
| WO2011136637A1 (en) * | 2010-04-27 | 2011-11-03 | N.V. Nutricia | Use of human milk oligosaccharides in infant nutrition |
| CA2798675A1 (en) | 2010-06-01 | 2011-12-08 | Glycom A/S | Polymorphs of 2'-o-fucosyllactose and producing thereof |
| EP2465509A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
| EP2455387A1 (en) * | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
| EP2465508A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
| EP2658547A1 (en) | 2010-12-31 | 2013-11-06 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
| US11337990B2 (en) * | 2010-12-31 | 2022-05-24 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
| EP3338784B1 (en) | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
| MX356994B (es) | 2010-12-31 | 2018-06-22 | Abbott Lab | Composiciones nutricionales que comprenden los oligosacaridos de leche humana y los nucleotidos y los usos de las mismas para tratar y/o prevenir la infeccion viral enterica. |
| SG191799A1 (en) | 2010-12-31 | 2013-08-30 | Abbott Lab | Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof |
| DK2658549T3 (da) * | 2010-12-31 | 2020-06-29 | Abbott Lab | Fremgangsmåder til reduktion af incidensen af oxidativt stress under anvendelse af humane mælkeoligosaccharider, vitamin c og anti-inflammatoriske midler |
| US20120171166A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
| MY166946A (en) | 2010-12-31 | 2018-07-25 | Abbott Lab | Methods of using human milk oligosaccharides for improving airway respiratory health |
| US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
| US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
| US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
| US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
| US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
| US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
| US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| PH12013501501A1 (en) * | 2011-02-10 | 2019-10-07 | Nestec Sa | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk |
| JP6129821B2 (ja) * | 2011-05-13 | 2017-05-17 | グリコシン リミテッド ライアビリティー カンパニー | プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用 |
| DK3366143T3 (da) | 2011-06-20 | 2025-01-27 | Heinz Co Brands H J Llc | Probiotiske sammensætninger og fremgangsmåder |
| CN103813796A (zh) | 2011-07-22 | 2014-05-21 | 雅培制药有限公司 | 用于预防胃肠道损伤和/或促进胃肠道修复的低聚半乳糖 |
| CA2846603A1 (en) | 2011-08-29 | 2013-03-07 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| CN103889240B (zh) * | 2011-10-18 | 2016-09-14 | 雀巢产品技术援助有限公司 | 用于增加胰岛素敏感性和/或降低胰岛素抵抗性的组合物 |
| BR112014008425A2 (pt) * | 2011-10-18 | 2017-04-11 | Nestec Sa | composição para o uso na promoção de angiogênese intestinal e de absorção de nutriente e de tolerância a alimentação enteral e/ou na prevenção e/ou no tratamento de inflamação intestinal e/ou na recuperação após a lesão e a cirurgia intestinal |
| CN104780932A (zh) | 2012-02-29 | 2015-07-15 | 伊西康内外科公司 | 微生物区系的组合物及与其相关的方法 |
| SG11201406022YA (en) * | 2012-03-27 | 2014-10-30 | Abbott Lab | Methods for modulating cell-mediated immunity using human milk oligosaccharides |
| DK2708145T3 (en) * | 2012-09-14 | 2016-07-18 | Abbott Lab | Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals |
| WO2014130789A1 (en) | 2013-02-21 | 2014-08-28 | Children's Hospital Medical Center | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease |
| US10165788B2 (en) * | 2013-06-17 | 2019-01-01 | The Regents Of The University Of California | Methods and compositions for improved digestion of milk oligosaccharides |
| EP2815757A1 (en) * | 2013-06-17 | 2014-12-24 | Hestia Investments | Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa |
| WO2015071402A1 (en) | 2013-11-15 | 2015-05-21 | Nestec S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
| AU2014350144B2 (en) * | 2013-11-15 | 2019-11-21 | Société des Produits Nestlé S.A. | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk |
| MX2016006220A (es) | 2013-11-15 | 2016-08-08 | Nestec Sa | Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños nacidos por cesarea. |
| US10568896B2 (en) | 2013-11-19 | 2020-02-25 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US12318377B2 (en) | 2013-12-20 | 2025-06-03 | Seed Health, Inc. | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| HK1231398A1 (zh) | 2014-04-08 | 2017-12-22 | Abbott Laboratories | 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法 |
| CN114376234A (zh) | 2014-10-24 | 2022-04-22 | 进化生物系统股份有限公司 | 活化的双歧杆菌及其应用方法 |
| EP4529950A3 (en) | 2014-10-31 | 2025-08-20 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment |
| WO2016086151A1 (en) * | 2014-11-26 | 2016-06-02 | Abbott Laboratories | Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic |
| US10835544B2 (en) | 2014-12-08 | 2020-11-17 | Glycom A/S | Synthetic composition for regulating satiety |
| US10881674B2 (en) | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
| US10987368B2 (en) | 2014-12-08 | 2021-04-27 | Glycom A/S | Synthetic composition for preventing or treating CVD |
| CN107427054A (zh) | 2015-03-05 | 2017-12-01 | 雀巢产品技术援助有限公司 | 用于预防或治疗婴儿或幼儿的耳炎或支气管炎的组合物 |
| WO2016138911A1 (en) | 2015-03-05 | 2016-09-09 | Glycom A/S | Composition and method for treating acute respiratory tract infections |
| US10821124B2 (en) * | 2015-03-05 | 2020-11-03 | Societe Des Produits Nestle S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
| FI3264923T3 (fi) | 2015-03-05 | 2023-04-21 | Nestle Sa | Koostumuksia käytettäväksi ruoansulatuskanavan infektioiden ehkäisemisessä tai hoitamisessa imeväisillä tai nuorilla lapsilla |
| US10857167B2 (en) | 2015-04-28 | 2020-12-08 | Children's Hospital Medical Center | Use of oligosaccharide compositions to enhance weight gain |
| SG11201807809XA (en) | 2016-03-11 | 2018-10-30 | Evolve Biosystems Inc | A transient commensal microorganism for improving gut health |
| EP3471562A4 (en) * | 2016-06-15 | 2020-07-29 | Glycom A/S | Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders |
| WO2019031961A1 (en) | 2017-08-11 | 2019-02-14 | N.V. Nutricia | OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| EP3583858A1 (en) * | 2018-06-20 | 2019-12-25 | DuPont Nutrition Biosciences ApS | Compositions for treating or preventing gut barrier dysfunction |
| WO2019229711A1 (en) * | 2018-05-31 | 2019-12-05 | Glycom A/S | Mixture of hmos for treating autoimmune diseases |
| WO2020018949A2 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| EP3981256A4 (en) * | 2019-06-05 | 2023-01-25 | Morinaga Milk Industry Co., Ltd. | COMPOSITION |
| US12364721B2 (en) | 2019-09-24 | 2025-07-22 | Prolacta Bioscience, Inc. | Compositions and methods for treatment of inflammatory and immune diseases |
| JP2023502260A (ja) * | 2019-11-20 | 2023-01-23 | アボット・ラボラトリーズ | クロストリジウム・ディフィシル感染症を治療する栄養組成物 |
| CN112870233B (zh) * | 2019-11-29 | 2024-08-23 | 伊利伊诺科技(上海)有限责任公司 | 包含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
| CA3161779A1 (en) * | 2019-12-19 | 2021-06-24 | An-Katrien VYNCKIER | Compositions and methods for managing infections of a urinary tract |
| US20230149432A1 (en) * | 2020-04-03 | 2023-05-18 | Inner Mongolia Yili Industrial Group Co., Ltd. | Human Milk Oligosaccharides for Improving Resistance of Organism Against Staphylococcus Aureus Infection |
| WO2022100758A1 (zh) * | 2020-11-16 | 2022-05-19 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
| CN116195740A (zh) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | 可提升生物体对金黄色葡萄球菌感染抵御能力的益生元与益生菌组合物 |
| CN116195629A (zh) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | 婴儿双歧杆菌ylgb-1496在抗衰老、提高先天免疫方面的新应用 |
| KR20250036879A (ko) * | 2022-07-15 | 2025-03-14 | 디에스엠 아이피 어셋츠 비.브이. | Nmn 또는 nad+의 증가에 사용하기 위한 비피도박테리움 및 푸코실화된 hmo의 조합물 |
| AU2023348096A1 (en) * | 2022-09-27 | 2025-02-13 | Société des Produits Nestlé S.A. | Uses of bifidobacterium longum transitional microorganism |
| WO2025083288A1 (en) | 2023-10-19 | 2025-04-24 | N.V. Nutricia | Mixture of human milk oligosaccharides |
| WO2025083289A1 (en) | 2023-10-19 | 2025-04-24 | N.V. Nutricia | Mixture of human milk oligosaccharides |
| WO2025219497A1 (en) | 2024-04-19 | 2025-10-23 | Dsm Ip Assets B.V. | Combination comprising bifidobacterium bifidum ha-132 and human milk oligosaccharides |
| WO2025219496A1 (en) | 2024-04-19 | 2025-10-23 | Dsm Ip Assets B.V. | Nutritional composition comprising bifidobacterium longum ssp. infantis r0033 and human milk oligosaccharides |
| WO2025256999A1 (en) * | 2024-06-11 | 2025-12-18 | Chr. Hansen A/S | Composition comprising bifidobacterium longum subsp. infantis and human milk oligosaccharides |
| CN120000695B (zh) * | 2025-02-24 | 2025-11-04 | 合生元(广州)健康产品有限公司 | 2’-岩藻糖基乳糖和益生菌的组合物及其应用和产品 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| ES2102485T3 (es) * | 1992-07-06 | 1997-08-01 | Nestle Sa | Bacteria lactica. |
| ATE161181T1 (de) | 1992-07-06 | 1998-01-15 | Nestle Sa | Lactobacillus acidophilus enthaltende antigastritis-mittel |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| US6045854A (en) | 1997-03-31 | 2000-04-04 | Abbott Laboraties | Nutritional formulations containing oligosaccharides |
| WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
| US5902743A (en) * | 1998-03-20 | 1999-05-11 | Wisconsin Alumni Research Foundation | Probiotic bifidobacterium strain |
| US20020019991A1 (en) * | 1998-04-30 | 2002-02-14 | Abbott Laboratories | Compositions containing an alpha 1,2-fucose linkage and uses thereof |
| US6841149B1 (en) * | 1998-05-29 | 2005-01-11 | Agri-King, Inc. | Probiotic mixture intended for monogastric animals to control intestinal flora populations |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| CN1863463B (zh) * | 2003-06-23 | 2011-05-04 | 雀巢技术公司 | 用于促进肠道屏障成熟的营养组合物 |
| PL1675481T3 (pl) | 2003-10-24 | 2009-03-31 | Nutricia Nv | Kompozycja synbiotyczna dla niemowląt |
| EP1689348B1 (en) | 2003-12-05 | 2013-05-15 | Children's Hospital Medical Center | Oligosaccharide compositions and use thereof in the treatment of infection |
| US7137361B2 (en) | 2004-06-22 | 2006-11-21 | Federal-Mogul World Wide, Inc. | Cylinder head gasket with one-way coolant flow valve |
| EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
| EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| EP2388010A1 (en) * | 2006-03-10 | 2011-11-23 | N.V. Nutricia | Use of non-digestible saccharides for giving an infant the best start after birth |
| EP2117355B1 (en) | 2007-03-13 | 2017-04-26 | N.V. Nutricia | Method of improving skills with a composition comprising non-digestible saccharide |
| US8197872B2 (en) * | 2007-05-17 | 2012-06-12 | The Regents Of The University Of California | Human milk oligosaccharides to promote growth of beneficial gut bacteria |
| EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
| ES2395838T3 (es) * | 2007-12-21 | 2013-02-15 | Compagnie Gervais Danone | Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium |
-
2007
- 2007-12-17 EP EP07123390A patent/EP2072052A1/en not_active Withdrawn
-
2008
- 2008-06-16 PH PH12010501367A patent/PH12010501367B1/en unknown
- 2008-12-05 AU AU2008337646A patent/AU2008337646B2/en active Active
- 2008-12-05 MY MYPI2010002780A patent/MY185938A/en unknown
- 2008-12-05 US US12/808,053 patent/US9217133B2/en active Active
- 2008-12-05 BR BRPI0820837-9A patent/BRPI0820837A2/pt not_active Application Discontinuation
- 2008-12-05 EP EP08862982.9A patent/EP2234627B1/en not_active Revoked
- 2008-12-05 ES ES08862982.9T patent/ES2576642T3/es active Active
- 2008-12-05 SG SG2012092268A patent/SG186657A1/en unknown
- 2008-12-05 PT PT88629829T patent/PT2234627T/pt unknown
- 2008-12-05 CN CN2008801249067A patent/CN101909644A/zh active Pending
- 2008-12-05 PL PL08862982.9T patent/PL2234627T3/pl unknown
- 2008-12-05 CA CA2709396A patent/CA2709396A1/en not_active Abandoned
- 2008-12-05 WO PCT/EP2008/066850 patent/WO2009077352A1/en not_active Ceased
- 2008-12-05 MX MX2010006690A patent/MX2010006690A/es active IP Right Grant
- 2008-12-05 RU RU2010129685/15A patent/RU2486910C2/ru active
- 2008-12-08 UA UAA201008634A patent/UA102830C2/ru unknown
-
2010
- 2010-06-16 IN IN4311DEN2010 patent/IN2010DE04311A/en unknown
- 2010-07-16 ZA ZA2010/05088A patent/ZA201005088B/en unknown
-
2012
- 2012-08-17 US US13/588,745 patent/US20120308527A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0820837A2 (pt) | 2015-06-16 |
| WO2009077352A1 (en) | 2009-06-25 |
| SG186657A1 (en) | 2013-01-30 |
| US9217133B2 (en) | 2015-12-22 |
| MY185938A (en) | 2021-06-14 |
| US20120308527A1 (en) | 2012-12-06 |
| PL2234627T3 (pl) | 2016-12-30 |
| IN2010DE04311A (ru) | 2010-11-12 |
| EP2234627B1 (en) | 2016-05-25 |
| EP2234627A1 (en) | 2010-10-06 |
| MX315565B (ru) | 2010-09-10 |
| AU2008337646B2 (en) | 2014-07-17 |
| PT2234627T (pt) | 2016-07-26 |
| EP2072052A1 (en) | 2009-06-24 |
| CA2709396A1 (en) | 2009-06-25 |
| MX2010006690A (es) | 2010-09-10 |
| ES2576642T3 (es) | 2016-07-08 |
| AU2008337646A1 (en) | 2009-06-25 |
| PH12010501367B1 (en) | 2009-06-25 |
| UA102830C2 (ru) | 2013-08-27 |
| ZA201005088B (en) | 2017-03-27 |
| US20100260720A1 (en) | 2010-10-14 |
| RU2486910C2 (ru) | 2013-07-10 |
| CN101909644A (zh) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010129685A (ru) | Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом | |
| RU2010142003A (ru) | Синбиотическая смесь | |
| ES2652464T3 (es) | Composiciones que comprenden componentes probióticos y prebióticos y sales minerales, con lactoferrina | |
| RU2010153257A (ru) | Пробиотики для улудшения микробиоты пищеварительного тракта | |
| Yen et al. | Lactoferrin: an iron-binding antimicrobial protein against Escherichia coli infection | |
| RU2013128570A (ru) | Олигосахаридная композиция для лечения острых инфекций дыхательных путей | |
| US11478515B2 (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| RU2008136876A (ru) | Применение bifidobacterium longum для предупреждения и лечения воспаления | |
| EP3341001B1 (en) | Composition and method for treatment and prophylaxis of intestinal infection and inflammation | |
| Hatakka et al. | Probiotics in intestinal and non-intestinal infectious diseases-clinical evidence | |
| RU2011106319A (ru) | Пробиотики для увелечения секреции iga у младенцев, рожденных посредством кесарева сечения | |
| RU2017133795A (ru) | Композиции для применения в профилактике или лечении инфекций/воспалений в желудочно-кишечном тракте у младенцев или детей младшего возраста | |
| RU2009139657A (ru) | Снижение риска диареи | |
| RU2008139598A (ru) | Синбиотическая смесь | |
| RU2019139073A (ru) | Синергетическая выработка бутирата, связанная со сложностью смеси огм для применения у младенцев или детей младшего возраста в медицинских целях | |
| RU2010123174A (ru) | Профилактика и лечение вторичных инфекций после вирусной инфекции | |
| RU2017134672A (ru) | Композиции для применения в улучшении консистенции или частоты стула у младенцев или детей младшего возраста | |
| CN105283195A (zh) | 用于治疗过敏患者的感染的合生素组合物 | |
| JP2012520325A5 (ru) | ||
| JP2014512376A (ja) | 胃酸過多症の薬理学的処置中に失われる胃のバリア効果を回復させることができるプロバイオティック細菌を含む組成物 | |
| RU2009139669A (ru) | Синбиотик для улучшения кишечной микробиоты | |
| RU2009100890A (ru) | Профилактика и лечение воспаления среднего уха с помощью непатогенных штаммов бактерий | |
| IT201900014388A1 (it) | Consorzio di probiotici | |
| WO2014184644A9 (en) | Composition comprising lactic acid bacteria and/or bifidobacteria for use in the preventive and/or curative treatment of bacterial infections and/or inflammations of the urinary tract and/or prostate which are the cause of prostatitis and prostatic hypertrophy | |
| RU2019109938A (ru) | Питательная композиция для младенцев и/или детей младшего возраста, содержащая олигосахариды |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| QZ41 | Official registration of changes to a registered agreement (patent) |
Free format text: LICENCE FORMERLY AGREED ON 20101006 Effective date: 20150710 |
|
| QC41 | Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right |
Free format text: LICENCE FORMERLY AGREED ON 20101006 Effective date: 20170316 |
|
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20190916 |